Ocular pharmacokinetic/pharmacodynamic modeling for bunazosin after instillation into rabbits

Pharmaceutical Research

Volumn 21, Issue 5, 2004, Pages 770-776

  Sakanaka, Koji ^a,b   Kawazu, Kouichi ^b   Tomonari, Masahide ^a   Kitahara, Takashi ^a   Nakashima, Mikiro ^a   Kawakami, Shigeru ^a   Nishida, Koyo ^a   Nakamura, Junzo ^a   Sasaki, Hitoshi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bunazosin; Eye; Indirect response; Intraocular pressure; Pharmacokinetic pharmacodynamic model

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ANTIHYPERTENSIVE ACTIVITY; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA; DRUG INSTILLATION; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAOCULAR PRESSURE; LACRIMAL FLUID; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THEORETICAL MODEL; TONOMETER;

ADRENERGIC ALPHA-ANTAGONISTS; ALGORITHMS; ANIMALS; AQUEOUS HUMOR; EYE; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MODELS, BIOLOGICAL; QUINAZOLINES; RABBITS; TEARS;

EID: 3543015611     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000026426.20012.36     Document Type: Article

References (17)

1. H. Sasaki, K. Yamamura, T. Mukai, K. Nishida, J. Nakamura, M. Nakashima, and M. Ichikawa. Enhancement of ocular drug penetration. Crit. Rev. Ther. Drug Carrier Syst. 16:85-146 (1999).
2. K. Yamamura, H. Sasaki, M. Nakashima, M. Ichikawa, T. Mukai, and K. Nishida, and J. Nakamura. Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation. Pharm. Res. 16:1596-1601 (1999).
3. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4:879-885 (1981).
4. M. Sakurai, M. Araie, T. Oshika, M. Mori, N. Shoji, and K. Masuda. Effects of topical application of UF-021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit. Jpn. J. Ophthalmol. 37:252-258 (1993).
5. K. Yamaoka and T. Nakagawa. A nonlinear least squares program based on differential equations. MULTI (RUNGE), for microcomputers. J. Pharmacobiodyn. 6:595-606 (1983).
6. T. Takagi, N. Sun, Y. Kuwayama, R. Yamamoto, M. Tanaka, T. Kusunoki, Y. Shimizu, and R. Manabe. The effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dynamics in human. Acta Soc. Ophthalmol. Jpn. 95:273-278 (1991).
7. G. L. Zhan, C. B. Toris, C. B. Camras, Y. L. Wang, and M. E. Yablonski. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. J. Ocul. Pharmacol. Ther. 14:217-228 (1998).
8. N. L. Dayneka, V. Garg, and W. J. Jusko. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478 (1993).
9. J. M. Conrad and J. R. Robinson. Aqueous chamber drug distribution volume measurement in rabbits. J. Pharm. Sci. 66:219-224 (1977).
10. S. F. Nilsson. The uveoscleral outflow routes. Eye 11:149-154 (1997).
11. 1-adrenoceptor blocker, in rabbits and cats. Acta Soc. Ophthalmol Jpn. 95:746-751 (1991).
12. M. C. Makoid and J. R. Robinson. Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye. J. Pharm. Sci. 68: 435-443 (1979).
13. R. D. Schoenwald. Ocular drug delivery. Pharmacokinetic considerations. Clin. Pharmacokinet. 18:255-269 (1990).
14. A. Kato and S. Iwata. Corneal permeability to bunazosin in rabbits. J. Pharmacobiodyn. 11:181-185 (1988).
15. H. Derendorf and B. Meibohm. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16:176-185 (1999).
16. Y. Kimoto, M. Nozaki, and T. Itoh. Actions of the alpha-1 adrenoceptor blocker bunazosin on the norepinephrine-induced contraction of smooth muscles in the rabbit proximal urethra. J. Pharmacol. Exp. Ther. 241:1017-1022 (1987).
17. Y. Yamada, K. Matsuyama, K. Ito, Y. Sawada, and T. Iga. Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. J. Pharmacokinet. Biopharm. 23: 463-478 (1995).